[go: up one dir, main page]

AR077908A1 - OXADIAZOL COMPOUNDS AS S1P MODULATORS - Google Patents

OXADIAZOL COMPOUNDS AS S1P MODULATORS

Info

Publication number
AR077908A1
AR077908A1 ARP100103076A ARP100103076A AR077908A1 AR 077908 A1 AR077908 A1 AR 077908A1 AR P100103076 A ARP100103076 A AR P100103076A AR P100103076 A ARP100103076 A AR P100103076A AR 077908 A1 AR077908 A1 AR 077908A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
phenyl
cyclohexyl
optionally
Prior art date
Application number
ARP100103076A
Other languages
Spanish (es)
Inventor
Shannon R Fixx-Stenzel
Adrian D Hobson
Kevin R Woller
Kevin P Cusack
Eric C Breinlinger
Robert H Stoffel
Shannon R Fix-Stenzel
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR077908A1 publication Critical patent/AR077908A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos de oxadiazol, composiciones farmacéuticas que contienen dichos compuestos y uso de dichos compuestos o de dichas composiciones como agonistas o antagonistas de los receptores unidos a la proteína G de la familia S1P, para tratar enfermedades asociadas con la modulacion de la actividad de los receptores de la S1P, particularmente al proveer un efecto de inmunosupresion beneficioso. Reivindicacion 1: Un compuesto caracterizado porque es de formula (1) sales aceptables farmacéuticamente, metabolitos biologicamente activos, solvatos, hidratos, prodrogas, racematos, enantiomeros o estereoisomeros del mismo, donde L es una union o alquilo C1-3 opcionalmente sustituido; R1 es -C(O)-NH-fenilo, -NH-C(O)-furanilo, -NH-S(O)2-fenilo opcionalmente sustituido, -O-alquilo C1-3 opcionalmente sustituido, -S-alquilo C1-3 opcionalmente sustituido, alquilo C2-6 opcionalmente sustituido, amino opcionalmente sustituido, cicloalquilo C3-6 opcionalmente sustituido, -(CH2)alquilo C3, tetrahidrobenzofuranilo opcionalmente sustituido, furanilo opcionalmente sustituido, tetrahidrofuranilo opcionalmente sustituido, 2,3-dihidroisoindolilo opcionalmente sustituido, isoindolinilo opcionalmente sustituido, imidazolilo opcionalmente sustituido, 5,6-dihidro imidazo[1,2-a]pirazinilo opcionalmente sustituido, imidazo[1,2-a]pirazinilo opcionalmente sustituido, indolilo opcionalmente sustituido, isoxazolilo opcionalmente sustituido, morfolinilo opcionalmente sustituido, naftilo opcionalmente sustituido, fenilo opcionalmente sustituido, -O-CH2-fenilo opcionalmente sustituido, -O-fenilo opcionalmente sustituido, -O-fenilo opcionalmente sustituido, piperidinilo opcionalmente sustituido, pirazolilo opcionalmente sustituido, piridinilo opcionalmente sustituido, pirimidinilo opcionalmente sustituido, pirrolidinilo opcionalmente sustituido, 1,2,3,4-tetrahidroisoquinolinilo opcionalmente sustituido, quinolinilo opcionalmente sustituido, 3,4-dihidroquinolinilo opcionalmente sustituido, 3,4-dihidroisoquinolinilo opcionalmente sustituido, 5,6,7,8-tetrahidroimidazo[1,2-a]pirazinilo opcionalmente sustituido, pirrolilo opcionalmente sustituido, pirrolo[2,3-b]piridinilo opcionalmente sustituido, quinolinilo opcionalmente sustituido, tiazolilo opcionalmente sustituido o tienilo opcionalmente sustituido; R2 es Br, Cl, CF3, CN, o -O-alquilo C1-2; R3 es alquilo C3-8 opcionalmente sustituido, alquilo C2-6deuterado, alquenilo C4-5, alquinilo C4-5, cicloalquilo C3-6 opcionalmente sustituido, alquilo C2-3 opcionalmente sustituido-O-alquilo C1-3 opcionalmente sustituido, alquilo C1-3 opcionalmente sustituido-imidazolilo, alquilo C1-3opcionalmente sustituido-morfolinilo, alquilo C1-3 opcionalmente sustituido-fenilo opcionalmente sustituido, alquilo C1-3 opcionalmente sustituido-piperazinilo opcionalmente sustituido, alquilo C1-3 opcionalmente sustituido-pirrolidinilo, alquilo C1-3 opcionalmente sustituido-piperidinilo, alquilo C1-3 opcionalmente sustituido-tienilo, tetrahidrofuranilo o tiazolilo opcionalmente sustituido; y R6 es H; con las siguientes condiciones R1 no está sustituido con ciclohexilo opcionalmente sustituido, -C(O)ciclohexilo o -NH-ciclohexilo; cuando L es alquilo C1-3, R1 no es isoxazolilo opcionalmente sustituido; cuando R3 es (C1)alquilo opcionalmente sustituido, L-R1 no es ciclohexilo o -CH2-ciclohexilo; y con la condicion de que el compuesto no sea un compuesto de formula (2) o (3).Oxadiazole compounds, pharmaceutical compositions containing said compounds and use of said compounds or of said compositions as agonists or antagonists of the G protein-bound receptors of the S1P family, to treat diseases associated with the modulation of the activity of the receptors of S1P, particularly by providing a beneficial immunosuppression effect. Claim 1: A compound characterized in that it is of formula (1) pharmaceutically acceptable salts, biologically active metabolites, solvates, hydrates, prodrugs, racemates, enantiomers or stereoisomers thereof, wherein L is an optionally substituted C1-3 alkyl or alkyl; R1 is -C (O) -NH-phenyl, -NH-C (O) -furanyl, -NH-S (O) 2-optionally substituted phenyl, -O-optionally substituted C1-3 alkyl, -S-C1 alkyl -3 optionally substituted, optionally substituted C2-6 alkyl, optionally substituted amino, optionally substituted C3-6 cycloalkyl, - (CH2) C3 alkyl, optionally substituted tetrahydrobenzofuranyl, optionally substituted furanyl, optionally substituted tetrahydrofuranyl, optionally substituted 2,3-dihydroisoindolyl, optionally substituted isoindolinyl, optionally substituted imidazolyl, optionally substituted 5,6-dihydro imidazo [1,2-a] pyrazinyl, optionally substituted imidazo [1,2-a] pyrazinyl, optionally substituted indolyl, optionally substituted isoxazolyl, optionally substituted morpholinyl, naphthyl optionally substituted, optionally substituted phenyl, -O-CH2-optionally substituted phenyl, -O-optionally substituted phenyl, -O-optionally substituted phenyl, optionally substituted piperidinyl , optionally substituted pyrazolyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted pyrrolidinyl, optionally substituted 1,2,3,4-tetrahydroisoquinolinyl, optionally substituted quinolinyl, optionally substituted 3,4-dihydroquinolinyl, optionally substituted 3,4-dihydroisoquinolinyl, 5 , Optionally substituted 6,7,8-tetrahydroimidazo [1,2-a] pyrazinyl, optionally substituted pyrrolyl, optionally substituted pyrrolo [2,3-b] pyridinyl, optionally substituted quinolinyl, optionally substituted thiazolyl or optionally substituted thienyl; R2 is Br, Cl, CF3, CN, or -O-C1-2 alkyl; R3 is optionally substituted C3-8 alkyl, C2-6 deuterated alkyl, C4-5 alkenyl, C4-5 alkynyl, optionally substituted C3-6 cycloalkyl, optionally substituted C2-3 alkyl-optionally substituted C1-3 alkyl, C1- alkyl 3 optionally substituted-imidazolyl, optionally substituted C1-3 alkyl-morpholinyl, optionally substituted C1-3 alkyl-optionally substituted phenyl, optionally substituted C1-3 alkyl-optionally substituted piperazinyl, optionally substituted C1-3 alkyl-pyrrolidinyl, optionally C1-3 alkyl substituted-piperidinyl, optionally substituted C1-3 alkyl-thienyl, tetrahydrofuranyl or optionally substituted thiazolyl; and R6 is H; under the following conditions R1 is not substituted with optionally substituted cyclohexyl, -C (O) cyclohexyl or -NH-cyclohexyl; when L is C1-3 alkyl, R1 is not optionally substituted isoxazolyl; when R3 is (C1) optionally substituted alkyl, L-R1 is not cyclohexyl or -CH2-cyclohexyl; and with the proviso that the compound is not a compound of formula (2) or (3).

ARP100103076A 2009-12-08 2010-08-23 OXADIAZOL COMPOUNDS AS S1P MODULATORS AR077908A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26767909P 2009-12-08 2009-12-08

Publications (1)

Publication Number Publication Date
AR077908A1 true AR077908A1 (en) 2011-09-28

Family

ID=44145850

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103076A AR077908A1 (en) 2009-12-08 2010-08-23 OXADIAZOL COMPOUNDS AS S1P MODULATORS

Country Status (9)

Country Link
EP (1) EP2509424A4 (en)
JP (1) JP2013512951A (en)
CN (1) CN102762102A (en)
AR (1) AR077908A1 (en)
CA (1) CA2783851A1 (en)
MX (1) MX2012006667A (en)
TW (1) TW201120016A (en)
UY (1) UY32853A (en)
WO (1) WO2011071570A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2184989B1 (en) 2007-08-13 2015-05-06 Monsanto Technology LLC Compositions and methods for controlling nematodes
AU2012304661A1 (en) 2011-09-08 2014-04-03 Allergan, Inc. 3-(4-(5-phenyl-1,2,4-oxadiazol-3-yl)phenoxy)propan-2-ol derivatives as sphingosine-1 phosphate receptors modulators
ES2649475T3 (en) 2013-03-15 2018-01-12 Idorsia Pharmaceuticals Ltd Pyridin-4-yl derivatives
US9828351B2 (en) * 2014-06-26 2017-11-28 Monash University Enzyme interacting agents
US12209072B2 (en) 2018-09-18 2025-01-28 Bristol-Myers Squibb Company Cyclopentyl acids as LPA antagonists
CN112702998A (en) * 2018-09-18 2021-04-23 百时美施贵宝公司 Cycloheptanoic acids as LPA antagonists
ES2941774T3 (en) 2018-09-18 2023-05-25 Bristol Myers Squibb Co Oxabicyclo acids as LPA antagonists
CN109369620B (en) * 2018-12-22 2020-04-14 山东大学 Pyridine compound and its preparation method and anti-gastric cancer application
CN109776443B (en) * 2019-03-25 2022-09-27 上海万巷制药有限公司 Oxadiazole compound with antioxidant effect and preparation method thereof
CN114728927B (en) 2019-11-19 2025-08-29 莫达戈有限公司 Compounds for the diagnosis, treatment and prevention of diseases associated with aggregation of alpha-synuclein
UY38964A (en) 2019-11-25 2021-06-30 Novartis Ag DERIVATIVES OF 1,2,4-OXADIAZOLE AS AGONISTS OF THE X LIVER RECEPTOR, THEIR USES AND RELATED METHODS CROSS REFERENCE TO RELATED APPLICATIONS
CN115260173B (en) * 2021-04-30 2024-08-30 厦门宝太生物科技股份有限公司 Cyclopentanoindole branched acid derivative and preparation method and application thereof
CN113662938B (en) * 2021-09-26 2022-08-16 广西科技大学 Application of amine derivative in preparation of anti-tumor pharmaceutical composition
WO2023118253A1 (en) * 2021-12-23 2023-06-29 Chiesi Farmaceutici S.P.A. Cyclohexane acid derivatives as lpa receptor inhibitors
EP4649080A1 (en) * 2023-01-13 2025-11-19 Oppilan Pharma Ltd. Preparation of an s1p receptor modulator
CN116444454B (en) * 2023-06-16 2023-09-12 中国医学科学院医药生物技术研究所 N-hydroxyamidine derivatives, preparation methods and applications, tumor immunotherapy drugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI404706B (en) * 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd Novel thiophene derivatives
BRPI0711358A2 (en) * 2006-05-09 2011-09-27 Pfizer Prod Inc cycloalkylamino acid derivatives and their pharmaceutical compositions
DK2069335T3 (en) * 2006-09-08 2013-02-18 Actelion Pharmaceuticals Ltd PYRIDIN-3-YLD DERIVATIVES AS IMMUNO MODULATORS
AU2007334436A1 (en) * 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
AU2009220893A1 (en) * 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
GB0911130D0 (en) * 2009-06-26 2009-08-12 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
MX2012006667A (en) 2012-10-15
WO2011071570A1 (en) 2011-06-16
JP2013512951A (en) 2013-04-18
CA2783851A1 (en) 2011-06-16
EP2509424A4 (en) 2013-09-04
UY32853A (en) 2011-06-30
TW201120016A (en) 2011-06-16
EP2509424A1 (en) 2012-10-17
CN102762102A (en) 2012-10-31

Similar Documents

Publication Publication Date Title
AR077908A1 (en) OXADIAZOL COMPOUNDS AS S1P MODULATORS
PE20091712A1 (en) DERIVATIVES OF AZETIDINE AND CYCLOBUTANE AS JAK INHIBITORS
PE20121815A1 (en) PIRROLO-PYRIMIDINE COMPOUNDS AS CDK4 / 6 INHIBITORS
ES3034431T3 (en) Bicyclic heteroaryl derivatives as mnk1 and mnk2 modulators and uses thereof
AR073263A1 (en) DERIVATIVES OF PIRIDINE AND ITS USE IN DIAGNOSIS OF IMAGES BY PET
PE20151539A1 (en) NEW DERIVATIVES OF PIRAZOLE
AR067757A1 (en) IMIDAZO DERIVATIVES [4,5-C] PIRIDIN-2-ONA, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCEDURE FOR THE PREPARATION AND USE OF THE SAME AS ANTIVIRAL AGENTS.
AR067090A1 (en) SPIRICICLES AS INHIBITORS OF THE 11- BETA HYDROXIESTEROID DEHYDROGENASE TYPE 1
PE20090060A1 (en) IMIDAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS PI3 KINASE AND mTOR INHIBITORS
PE20120121A1 (en) IMIDAZOPYRAZINE DERIVATIVES AS SYK INHIBITORS
PE20090370A1 (en) DERIVATIVES OF FUSED HETEROCYCLE AS KINASE INHIBITORS
AR087288A1 (en) TETRAHYDROPIRIDO-PYRIDINE AND TETRAHYDROPIRIDO-PYRIMIDINE COMPOUNDS AND THEIR USE AS C5A RECEPTOR MODULATORS
PE20121025A1 (en) BENZOXAZEPINE COMPOUNDS AS P13K INHIBITORS
PE20060842A1 (en) AMINO-IMIDAZOLONES FOR THE INHIBITION OF B-SECRETASE
PE20151249A1 (en) PYRAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF JAK KINASES
PE20081159A1 (en) INHIBITORS OF KINASES AND METHODS FOR THEIR USE
AR077463A1 (en) IMIDAZO DERIVATIVES [1, 2 - A] PIRAZINA AND ITS USE IN MEDICINES FOR THE TREATMENT OF PARASITARY DISEASES
AR076928A1 (en) DERIVATIVES OF 3H-PIRIDO [4, 3-D] PIRIMIDIN-4-ONA, A METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF DISEASES RELATED TO STRESS.
SV2010003779A (en) CYCLOPROPIL-POLYMERASE INHIBITORS REF. TYPE193 PCT / SLV / FD / 1VH
PE20190339A1 (en) 1H-PIRAZOLO [4,3-B] PYRIDINES AS INHIBITORS OF PDE1
PE20091436A1 (en) SULFONAMID DERIVATIVES SUBSTITUTED AS B1R MODULATORS
RU2013142881A (en) Imidazopyrazines
ES2530815T3 (en) Thiazolyl and oxazolyl isoquinolinones and methods for using them
AR087212A1 (en) CRTh2 ANTAGONISTS
RU2016119662A (en) PYRIDAZINE DERIVATIVES AS RORc MODULATORS

Legal Events

Date Code Title Description
FB Suspension of granting procedure